MedTrace Logo

Amyloid PET in Patients With Mild Cognitive Impairment and Early Dementia

NCT06402370 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2024-05-20

No results posted yet for this study

Summary

The National Institute on Aging together with the Alzheimer's Association (NIA-AA) recently proposed the ATN classification which is based upon the pathological processes present in Alzheimer's disease (amyloid, tau and neurodegeneration). The amyloid and tau status can be defined using cerebrospinal fluid analysis but also non-invasively using an amyloid or tau PET scan. The N status can be defined using an \[18F\]-FDG PET scan which is in Belgium part of standard of care. Recently, it has been demonstrated, using different amyloid PET tracers, that early-frame amyloid scans can be a surrogate for \[18F\]-FDG PET scan.

Conditions

Interventions

DIAGNOSTIC_TEST

PET scan

\[18F\]Vizamyl

Sponsors & Collaborators

  • University Hospital, Ghent

    lead OTHER

Principal Investigators

  • Donatienne Van Weehaeghe, MD PhD · UZ Gent

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-08
Primary Completion
2026-05-31
Completion
2026-05-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06402370 on ClinicalTrials.gov